Compare TY & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | ALMR |
|---|---|---|
| Founded | 1929 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1994 | 2026 |
| Metric | TY | ALMR |
|---|---|---|
| Price | $34.67 | $33.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.0K | ★ 385.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.53 | $21.58 |
| 52 Week High | $36.55 | $38.54 |
| Indicator | TY | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 54.08 |
| Support Level | $34.18 | $23.69 |
| Resistance Level | $35.87 | $38.54 |
| Average True Range (ATR) | 0.39 | 2.09 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 13.19 | 45.86 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.